Sangamo will provide framework for Functional Cure of HIV at ASGCT in May
At the American Society of Gene and Cell Therapy (May 15-18, 2013), Sangamo will be providing oral presentation on preliminary results of their Phase 2 for their SB-728-T therapeutic. Sangamo has already announced since last week Phase 2 results will be presented. However, decisions on acceptance by ASGCT was to be made by mid-March, which is today (per their website). You know it must be exceptional to get an Early Decision. If it is continuation and expansion of the unprecedented results they have presented so far for their Phase 1 results (focusing on safety and efficacy), I think you will see the exceptional Phase 2 results which provides framework for a HIV Functional Cure.